In this CME episode, Dr. Andrew Cutler interviews Dr. Jeffrey Strawn about the role of pharmacogenomic testing in guiding treatment of major depressive disorder (MDD). They discuss how pharmacogenomic testing works, the impact of failed treatments and side effects on patients with MDD, and the clinical applications and future directions of pharmacogenomic testing.

Create a free NEI guest account and obtain CME/CE by participating in this activity here: https://nei.global/e209-cme

Never miss an episode!🎙SUBSCRIBE to the NEI Podcast– available on all your favorite platforms: https://nei.global/podcast

Interested in Psychopharmacology? Learn about the NEI Master Psychopharmacology Program: https://nei.global/mpp

Stay updated with email alerts and join our conversations on social. Follow us on:

YouTube: https://nei.global/youtube

Instagram: https://nei.global/instagram

LinkedIn: https://nei.global/linkedin

Facebook: https://nei.global/facebook

X: https://nei.global/twitter

E209 - (CME) Harnessing Pharmacogenomic Testing as a Tool in Major Depressive Disorder Treatment